

Factors Associated with Poor Glycemic Control among Patients with Type 2 Diabetes in the Southeast Region of Brazil

Débora Gonçalves da Silva*, Luiz Alberto Simeoni, Angélica Amorim Amato

School of Health Science, University of Brasilia, Brazil

Abstract Background: Brazil is an upper middle-income country with the fourth higher prevalence of diabetes and the fifth in diabetes-related health expenditure. By monitoring the factors related to glycemic control is critical to design and implement policies to reduce the morbidity and mortality of the disease. The aim of this study was to investigate the status of glycemic control and the factors associated with poor glycemic control among diabetics from the Southeast of Brazil. Methods: Data from 656 patients with diabetes attending public and private Endocrinology units were analyzed after reviewing medical records for sociodemographic, clinical and biochemical features in the northwest region of Minas Gerais, Brazil. We also investigated the factors associated with poor glycemic control among patients with type 2 diabetes (T2D). Results: Most patients were female with T2D, median age of 55.1 years and a median time since diabetes diagnosis of less than 5 years. Over 60% of patients had glycosylated hemoglobin (HbA1c) levels over 7%. Factors associated with poor glycemic control among patients with T2D were schooling for less than 4 years, longer time since diabetes diagnosis, treatment with insulin and less frequent follow-up with endocrinologists and dietitians. Conclusion: Our findings confirm data from previous studies indicating that educational level, duration of diabetes, and less frequent follow-up by endocrinologists and dietitians may negatively affect glycemic control. It is therefore possible that health policies focusing patients with these features might favorably affect glycemic control among patients with T2D.

Keywords Diabetes, Glycemic control

1. Introduction

Diabetes is one of the most prevalent chronic-degenerative diseases worldwide. According to the International Diabetes Federation, approximately 415 million people were affected in 2015, and this number should reach 642 million by 2040. The disease is also a major concern due to its high mortality rates and health care associated costs [1].

Diabetes has historically had a higher burden in high-income countries, but the disease is growing rapidly in low-to-middle-income countries. Data from a large study analyzing 198 countries between 2000 and 2008 indicated that overall diabetes prevalence grew by two percentage points between 1990 (7.4%) and 2008 (9.4%), with a similar level of growth for low-to-middle income countries (7.5–9.3%) [2]. Accordingly, another study involving 4372 million participants in 200 countries showed that low and

middle-income countries replaced European countries on the list of the top ten countries with the highest prevalence of diabetes [3].

This shift in diabetes prevalence in lower income countries may have a major impact in the morbidity and mortality of the disease, given to the many problems these countries face in providing appropriate care for patients with the disease [4]. Brazil is an upper middle-income country with the third highest number of children with type 1 diabetic (T1D) and the fourth largest number of people with type 2 diabetes (T2D) [1, 5]. Despite the well-established impact of glycemic control on the development of the vascular complications of diabetes, most patients do not achieve treatment goals, similarly to the situation worldwide [6, 7]. This underscores the need for more effective approaches to manage the disease, centered on each local scenario to establish factors related to poor glycemic control.

Paracatu and João Pinheiro are the cities with the first (91,724) and third (48,472) largest number of inhabitants in the Northwest of the state of Minas Gerais, respectively. Both cities have a gross domestic product *per capita* of \$7,234, slightly below the overall Brazilian gross domestic product per capita [8]. The aim of this study was to describe variables related to glycemic control in patients from these

* Corresponding author:

deboraendocrino@yahoo.com (Débora Gonçalves da Silva)

Published online at <http://journal.sapub.org/diabetes>

Copyright © 2018 The Author(s). Published by Scientific & Academic Publishing

This work is licensed under the Creative Commons Attribution International

License (CC BY). <http://creativecommons.org/licenses/by/4.0/>

two cities, and examine the factors related to poor control.

2. Methods

This was a cross-sectional study based on primary data collected from the medical records of all patients with diabetes who were attending the Endocrinology Outpatient Units from the Cities of Paracatu and Joao Pinheiro, from June to December of the year 2016. The diagnosis of diabetes was defined according to the American Diabetes Association (ADA) criteria [9] or when it was clearly stated in the medical records that the patient had a clinical diagnosis of the disease and was receiving anti-hyperglycemic treatment. We excluded pregnant women and patients without glycosylated hemoglobin (HbA1c) assessment of the previous 12 months.

A structured questionnaire was used to collect information about socio-demographic, lifestyle, clinical, biochemical and diabetes follow-up characteristics. The study was approved by the local Ethics Committee of the Hyarte Education Center from Atenas Faculty, in Paracatu, and was performed according to Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines [10].

Statistical analysis

The planned sample size was 563 subjects with diabetes. We determined this sample size considering the estimated prevalence of diabetes of 10.2% in Brazil [1], an absolute precision of 2.5% and a level of significance of 5%.

Data from the questionnaires were tabulated to generate a database. Qualitative data were described as frequencies and quantitative data were described as median and interquartile range, since they were not normally distributed, as assessed using the Shapiro-Wilk test. Glycemic control was defined as satisfactory or not on the basis of HbA1c levels (≤ 7 and $> 7\%$, respectively). Participants with satisfactory or unsatisfactory glucose control were compared with respect to socio-demographic, lifestyle and clinical variables using the Fisher or chi-squared tests. Statistical significance was considered when p values were less than 0.05. All tests were performed using the software GraphPad Prism (version 6.0).

3. Results

We reviewed the medical records from a total of 656 patients (54 with T1D and 602 with T2D), and their demographic and clinical characteristics are shown in Table 1. The median age varied with the type of dysglycemia and most patients were female, particularly those with T2D. Most patients with T1D were of normal weight, had less than 5 or from 10 to 20 years since the diagnosis of the disease and self-monitored blood glucose levels frequently. Patients with T2D were mostly overweight or obese, had less than 5 years since diabetes diagnosis and did not self-monitor blood glucose levels. Moreover, most patients did not have smoking or drinking habits, and were sedentary.

Table 1. Demographic and clinical characteristics of the study participants, according to the type of diabetes

Type DM/Variables	T1D (n=54)	T2D (n =602)
Age – yr	18	58
Female sex – no (%)	30 (56%)	410 (68%)
BMI – kg/m ²		
< 18.5	3 (6%)	1 (0%)
18.5-24.9	39 (72%)	103 (17%)
25-29.9	8 (15%)	212 (35%)
30-34.9	4 (47%)	146 (24%)
35-49.9	0 (0%)	71 (12%)
≥ 40	0 (0%)	41 (6%)
Time since diagnosis – yr		
< 5	24 (44%)	317 (53%)
5-9.9	9 (17%)	115 (19%)
10-19.9	14 (26%)	127 (21%)
≥ 20	7 (13%)	43 (7%)
Exercise habits – min/wk		
None	27 (50%)	402 (67%)
< 50	5 (9%)	30 (5%)
50-150	15 (28%)	108 (18%)
> 150	7 (13%)	62 (10%)
Alcohol drinking status – n (%)		
Never	38 (70%)	319 (53%)
Current	12 (22.20%)	154 (25.50%)
Former	5 (7.40%)	129 (21.50%)
Smoking status – n (%)		
Never	44 (81%)	360 (60%)
Current	6 (11%)	46 (7.60%)
Former	4 (8%)	196 (32.40%)
SMBG – n (%)	53 (98%)	279 (45%)
Sweetener use – n (%)	45 (83%)	357 (59%)

BMI: body mass index; SMBG: self monitoring of blood glucose.

Table 2 shows the characteristics of the patients related to diabetes treatment. The most frequent pharmacological treatment of T2D was metformin, followed by insulin and sulfonylureas. Few patients with T1D were being treated with metformin in addition to insulin. The frequency of self-monitoring of blood glucose was variable, but higher among patients with T1D. Most patients were being followed up by endocrinologists one to two times per year, whereas the frequency of those being followed up by dietitians was smaller.

Median fasting glucose, post-prandial and Hb1Ac levels were above treatment goals, particularly among patients with T1D. Median values of total cholesterol, LDL-cholesterol and triglyceride levels were overall satisfactory (Table 3).

None of the sociodemographic and clinical variables investigated herein were associated with glycemic control among patients with T1D (data not shown). Among patients with T2D, schooling below 4 years and treatment with insulin were significantly associated with poor glycemic

control, whereas time since diagnosis of less than 10 years, follow up by dietitians and endocrinologists were associated with satisfactory glucose control (Table 4).

Table 2. Characteristics related to diabetes treatment, according to the type of diabetes

Type DM/Variables	T1D (n =54)	T2D (n = 602)
Insulin treatment – no (%)	53 (98%)	232 (38.5%)
Duration of insulin treatment – no (%)		
< 5 yr	24 (44%)	155 (67%)
5 – 10 yr	9 (16%)	31 (13%)
10 – 20 yr	14 (26%)	32 (14%)
> 20 yr	7 (14%)	14 (6%)
Treatment with anti-hyperglycemic agents – no (%)		
Metformin monotherapy	4 (7.4%)	286 (47.5%)
Sulphonylurea monotherapy	0 (0%)	15 (2.5%)
Dual therapy	0 (0%)	189 (31.4%)
Triple therapy	0 (0%)	15 (2.5%)
Frequency of SMBG – no (%)		
< 3 / wk	5 (9.25%)	99 (16.5%)
3 – 5 / wk	10 (17.5%)	67 (11.2%)
5 – 10 / wk	5 (9.25%)	44 (7.3%)
> 10 / wk	34 (64%)	69 (11.5%)
Access to glucose test strips in the public health system – no (%)		
< 50 strips / mo	0 (0%)	25 (4.15%)
50 – 90 strips / mo	9 (17%)	152 (25.2%)
> 90 strips / mo	31 (57.4%)	7 (1.16%)
Follow up with a dietitian – no (%)		
Never	12 (22.2%)	277 (46%)
1 – 2 / yr	38 (70.4%)	303 (50%)
3 – 5 / yr	4 (7.6%)	16 (3%)
Monthly	0 (0%)	6 (1%)
Follow up with a diabetes specialist – no (%)		
Never	0 (0%)	4 (0.66%)
1 – 2 / yr	30 (55.6%)	482 (80.06%)
3 – 5 / yr	22 (40.7%)	103 (17.10%)
Monthly	2 (3.7%)	13 (2.18%)

BMI: body mass index; SMBG: self-monitoring blood glucose.

Table 3. Biochemical characteristics, according to the type of diabetes

Type DM/Variables	T1D (n=54)	T2D (n=602)
Fasting plasma glucose (mg/dL)	145	132.5
Post-prandial glucose plasma (mg/dL)	199	161
HbA1c (%)		
5 – 6.9	8 (14.81%)	213 (35.38%)
7 – 8.9	25 (46.3%)	210 (34.9%)
9 – 10.9	10 (18.51%)	107 (17.8%)
≥ 11	10 (18.51%)	72 (11.92%)

Total cholesterol (mg/dL)	170	167
LDL-cholesterol (mg/dL)	95	94
HDL-cholesterol (mg/dL)	46	57
Plasma triglycerides (mg/dL)	76	140
Urinary protein excretion (mg/24h)	109	100.5

HbA1c: glycated haemoglobin; HDL: high density lipoprotein; LDL: low density lipoprotein.

Table 4. Characteristics associated with poor glycemic control (HbA1 > 7%), type 2 diabetes

Characteristics	T2D (n =602)	
	OR (95%CI)	p
Male vs female	1.36 (0.9-2.0)	0.10
Age		
< 60 vs > 60 yr	0.03 (-0.03-0.11)	0.34
Married vs not married or widower	0.80 (0.53-1.19)	0.29
< 4 yr vs > 4 yr of school	1.46 (1.01-2.12)	0.04
Public vs private Endocrinology Unit	1.05 (0.72-1.49)	0.85
< 10 vs > 10 yr since diabetes diagnosis	0.27 (0.18-0.33)	<0.0001
> 50 min/wk vs no physical activity	0.72 (0.51-1.04)	0.09
BMI < 25 vs > 25 kg/m2	1.39 (0.93-2.06)	0.09
Use of sweetener	1.09 (0.77-1.58)	0.64
Arterial hypertension	1.23 (0.84-1.80)	0.28
Insulin treatment	6.14 (4.03-9.39)	<0.0001
Metformin treatment	0.76 (0.28-1.89)	0.66
< 3 vs > 3 / wk SMBG measures	0.63 (0.36-1.10)	0.14
Follow up with dietitian (1-3/yr vs never)	0.54 (0.39-0.77)	0.0005
Follow up with endocrinologist (3 – 5 vs 1 – 2 / yr)	0.47 (0.31-0.71)	0.0005

BMI: body mass index; SMBG: self-monitoring blood glucose

4. Discussion

In this cross-sectional study examining the socio-demographic and clinical characteristics of patients with diabetes in the Northwest region of Minas Gerais, we found that most patients attending outpatient Endocrinology Units were women with T2D and measures of glycemic control above target levels.

Our data are in agreement with those from a large Brazilian cross-sectional study involving 6,701 outpatients with T1D (15%) and T2D (85%) aged over 18 years indicating that most patients showed inadequate glycemic control. The authors also reported that patients with a longer period since diabetes diagnosis had worse control and that women who receiving insulin treatment were more likely to reach target HbA1c levels, despite no significant gender difference in glycemic control [11]. Similar studies were conducted in other middle-income countries. A cross-sectional Indian study including 16,607 patients with a mean age of 53 years reported a mean HbA1c level of 8.1%, and that only 31% reached the target value of less than 7%.

In concert with our findings, this study showed that treatment with insulin use was associated with poorer glycemic control. The study also found that advanced age, longer duration of diabetes and increased plasma triglyceride levels correlated with HbA1c levels above treatment goals [12].

We found a greater number of female patients with T2D attending outpatient Endocrinology Units. Although this finding does not imply a higher prevalence of the disease among women, it is in concert with data from a systematic review of 9 population-based studies involving diabetics at the age of 17 or more in the Caribbean region, which showed a higher prevalence of the disease among women. The authors attributed this to the higher frequency of diabetes risk factors among women, especially obesity [13].

We found that among patients with T2D those with less than four school years had a 46% increase in the chance of showing HbA1c levels above the target. Low education level is associated with overall poor health [14], and may also negatively affect glucose control [15, 16]. Similarly to our findings, a study in Israel involving 228,846 patients (mean age of 60 years) reported that poor glycemic control was associated with a lower education level, in addition to young age, longer duration of diabetes and belonging to an ethnic minority [17]. Moreover, higher education level was correlated with better knowledge about diabetes complications and greater adherence to diet, despite not having a better glycemic control [18]. However, the association between education level and diabetes control is not well-established, since other studies addressing this have shown no relationship, despite including a similar proportion of patients with HbA1c above the target levels [19].

We found a high frequency of obesity among patients with T2D, but not T1D. However, this frequency was lower than that observed in the United States. In the latter country, a study of electronic medical records data from 38 states between 2009 and 2011, with data from 259,595 patients, revealed that 47.8% of patients with T1D were obese, whereas 63.4% of those with T2D were obese. The authors also reported a high frequency of HbA1c above target levels [20].

Our findings also indicated that most patients with T1D and T2D were sedentary. Similar results were described in another Brazilian study carried out in Sao Paulo, with patients aged between 60-69 years, in which over 85% of the subjects reported no physical activity [21]. Exercise is a major component of T2D treatment due to its beneficial impact in insulin resistance. The effect of physical exercise in increasing insulin sensitivity is significantly maintained for about 60 hours after the exercise session and returns to baseline levels after 3 to 5 days. A trial conducted in France, with a 1-year follow-up intervention of 26 patients with T2D, involving a 3-week residential programme combining high exercise volume (15-20 hours/week) and restrictive diet (500 kcal/day), showed that 54% of patients stopped/decreased their medications following the intervention, whereas only 19% increased or introduced new drugs [22].

Although physical activity was shown to be protective

among patients with T2D, we found no association between physical activity and better glucose control. This is possibly explained by data collection from the medical records, which may have impaired a precise analysis of exercise intensity and regularity by study subjects, and by limited sample size. There was also no association between a smaller BMI and better glucose control, possibly explained by the small sample size.

Despite the data from our study and many others indicating that a low proportion of patients with diabetes reach glycemic goals, a study conducted in Brazil indicated a decline in diabetes-attributed mortality among adults aged 30 to 69 years, between 1996 and 2011, especially among women. The reasons for this are not completely understood, but it has been discussed that it may reflect increased primary coverage by the local health system, the introduction of the national plan for diabetes to ensure access to insulin since 1991, the national plan to reorganize the care of patients with diabetes and hypertension since 2001, and the national program of pharmaceutical provision for hypertension and diabetes since 2002, ensuring the distribution of tax-free supplies and drugs for patients with diabetes [23].

Our data also indicated that a high rate of diabetics treated with insulin do not achieve glycemic control goals. The association between insulin treatment and poor diabetes control is reported in other countries. A study conducted in a university hospital in Malaysia between 2009 and 2014, involving 220 diabetic patients with established cardiovascular disease and a mean age of 64 years, showed that insulin therapy was more frequent among patients with more severe comorbidities, and that insulin therapy was associated with poor disease control, with over 60% of the patients showing HbA1c greater than 8% [24]. However, it should be pointed that this study, similarly to ours, was cross-sectional and the relationship between insulin treatment and poor control may not be a causal one. Indeed, it is more likely that the inertia in starting insulin therapy and also in adjusting it to reach glycemic goals may lead to treatment being considered to patients with more comorbidities and difficulties in reaching control. In keeping with this, insulin was used predominantly in the group of patients with longer duration of diabetes, and this could reflect the difficulty in achieving adequate control in the setting of beta cell pancreatic failure, not due to insulin treatment per se.

5. Conclusions

Our findings indicate that most patients being followed up at public and private Endocrinology units in the Northwest region of Minas Gerais are middle-aged women, with poor glycemic control. Moreover, the factors associated with poor control among patients with T2D were a lower education level, prolonged time since diabetes diagnosis, insulin treatment and less frequent follow-up with dietitians and endocrinologists. However, these findings may not be generalizable to the overall population with diabetes given

that study participants were mostly women with less than 5 years since the diagnosis of the disease. Moreover, due to its cross-sectional design, it is not possible to establish the cause-effect relationship between these factors and glycemic control from the current findings. Notwithstanding, they point to the need of establishing an effective multidisciplinary program that can address the multiple variables that interfere in the complexity of this challenging disease, especially in lower-income countries.

REFERENCES

- [1] Ogurtsova K, Da Rocha Fernandes JD, Huang Y *et al.* IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. *Diabetes Res Clin Pract* 2017; 128: 40-50.
- [2] Sudharsanan N, Ali MK, Mehta NK, Narayan KMV. Population aging, macroeconomic changes and global diabetes prevalence 1990-2008. *Population Health Metrics* 2015; 13:33.
- [3] NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. *Lancet* 2016; 387:1513-30.
- [4] Bazargani YT, deBoer A, Leufkens HGM, Mantel-Teeuwisse AK. Selection of essential medicines for diabetes in low-middle income countries: a survey of 32 national essential medicine. *PLoS ONE* 2014; 9 (9): e106072.
- [5] World Bank. World Development Indicators 2013. Washington, DC: World Bank, 2013. doi: 10.1596/978-0-8213-9824-1.
- [6] Holman RR, Paul KS, Bethel A *et al.* 10-year follow-up of intensive glucose control in type 2 diabetes. *N Engl J Med* 2008; 359(15): 1577-1589.
- [7] DCCT/EDIC Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. *N Engl J Med* 2005; 353(25): 2643-2653.
- [8] Instituto Brasileiro De Geografia E Estatística. IBGE Censo Demográfico, 2010. Brasil, 2010.
- [9] American Diabetes Association. Standards of Medical Care in Diabetes. *Diabetes Care* 2016; 39 (1).
- [10] von Elm E, Altman DG, Egger M, Pocock SJ, *et al.* The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *J Clin Epidemiol* 2008; 61: 344-349.
- [11] Mendes ABV, Fittipaldi JOS, Neves RCS, *et al.* Prevalence and correlates of inadequate glycemic control: results from a nationwide survey in 6671 adults with diabetes in Brazil. *Acta Diabetol* 2010; 47:137-145.
- [12] Unnikrishnan R, Anjana RM, Deepa M *et al.* Glycemic control among individuals with self-reported Diabetes in India - The ICMR - INDIAB Study. *Diabetes Technology & Therapeutics* 2014; 16 (9): 596-603.
- [13] Sobers-Grannum N, Murphy MM, Nielsen A *et al.* Female gender is a social determinant of diabetes in the Caribbean: a systematic review and meta-anays. *PLOS ONE* 2015. DOI: 10.1371/journalpone.0126799.
- [14] The World Health Organization website. 2012. The determinants of health. Health Impact Assessment.
- [15] Maysaa K, Yousef K, Abdelkarim A-K *et al.* Factors associated with poor glycemic control among Jordanian patients with Type 2 diabetes. *Journal of Diabetes and Its Complications* 2010; 24: 84-89.
- [16] Ataur K, Zaki A-AL, Mohammad AA *et al.* Factors contributing to non-compliance among diabetics attending primary health centers in the Al Hasa district of Saudi Arabia. *J Family Community Med* 2012; 19(1): 26-32.
- [17] Feldman B, Cohen-Stavi CJ, Leibowitz M *et al.* Defining the role of medication adherence in poor glycemic control among a general population with diabetes. *PLOS one* 2014; 9: 108145.
- [18] Ahmad Ali S Al R. The role of educational level in glycemic control among patient with type 2 diabetes mellitus. *International Journal of Health Sciences* 2014; 8 (2).
- [19] Neme A-A, Yousef K, Aysha A. Glycemic Control and Its Determinants among Patients with type 2 Diabetes Mellitus Attending a Teaching Hospital. *J Diabetes Metab* 2011; 2 (4).
- [20] Bae JP, Late MJ, Nelson DR, Hoogwerf BJ. Obesity and glycemic control in patients with diabetes mellitus: analys of physican electronic health records in the US from 2009-2011. *Journal of Diabetes and its complications* 2016; 30 (2): 212-220.
- [21] Mendes TAB, Goldbaum M, Segri NJ *et al.* Diabetes mellitus: fatores associados à prevalência em idosos, medidas e práticas de controle e uso dos serviços de saúde em São Paulo, Brasil. *Cad. Saúde Pública* 2011; 27 (6): 1233-1243.
- [22] Lanhers C, Walther G, Chapier R, *et al.* Long-term cost reduction of routine medications following a residential programme combining physical activity and nutrition in the treatment of type 2 diabetes: a prospective cohort study. *BMJ Open* 2017; 7: e013763.
- [23] Schmidt MI, Duncan BB, Ishitani L *et al.* Trends in mortality due to diabetes in Brazil, 1996-2011. *Diabetol Metab Syndr*. 2015; 7(109).
- [24] Huri HZ, Ling DYH, Ahmad AW. Association between glycemic control and antidiabetic drugs in type 2 diabetes mellitus patients with cardiovascular complications. *Drug Design Development and Therapy* 2015; 9: 4735-4749.